Drug or treatment
Almonertinib clinical trials
As of November 12, 2026, Find a Trial lists 5 clinical trials of Almonertinib that are recruiting, in China. By phase: Phase 3 (3), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Neoadjuvant BL-B01D1 plus Almonertinib for resectable EGFR‑positive stage II–IIIB lung cancer | Phase 2 | Chengdu, Sichuan | Recruiting | Apr 30, 2025 |
| Almonertinib plus palbociclib for advanced KRAS‑mutant solid tumors | Phase 1/2 | Guangzhou, Guangdong | Recruiting | Apr 27, 2025 |
| Combining almonertinib and anlotinib for advanced lung cancer treatment | Phase 3 | Jinan, Shandong | Recruiting | Sep 21, 2023 |
| Comparing early and delayed brain radiotherapy with Almonertinib for lung cancer patients with brain metastases | Phase 3 | Guangdong, Guangzhou | Recruiting | Mar 14, 2023 |
| Assessing Almonertinib after Chemoradiation in Stage III Non-small Cell Lung Cancer | Phase 3 | Ji'nan, Shandong | Recruiting | Jul 7, 2021 |
All recruiting trials (5)
-
Neoadjuvant BL-B01D1 plus Almonertinib for resectable EGFR‑positive stage II–IIIB lung cancer
This trial will test whether giving BL-B01D1 together with Almonertinib before surgery, followed by Almonertinib after surgery, helps adults with resectable EGFR‑positive stage II–IIIB non‑small cell lung cancer.
-
Almonertinib plus palbociclib for advanced KRAS‑mutant solid tumors
We will test whether combining almonertinib with palbociclib is safe and shows early signs of benefit for adults with advanced solid tumors that have KRAS mutations.
-
Combining almonertinib and anlotinib for advanced lung cancer treatment
This study is testing a new combination of two drugs, almonertinib and anlotinib, to see if it can help people with advanced lung cancer who have certain genetic mutations.
-
Comparing early and delayed brain radiotherapy with Almonertinib for lung cancer patients with brain metastases
This study is testing whether giving brain radiotherapy right away or waiting a bit longer, along with a new lung cancer medication, helps people with brain metastases live longer and feel better.
-
Assessing Almonertinib after Chemoradiation in Stage III Non-small Cell Lung Cancer
This study is testing if a new drug called Almonertinib can help people with stage III non-small cell lung cancer feel better after they have received chemoradiation.
Quick answers
How many clinical trials of Almonertinib are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 3, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.